Article (Scientific journals)
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Jerusalem, Guy; Park, Yeon Hee; Yamashita, Toshinari et al.
2022In Cancer Discovery, 12 (12), p. 2754 - 2762
Peer Reviewed verified by ORBi
 

Files


Full Text
2754.pdf
Author postprint (5.43 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
trastuzumab deruxtecan; Receptor, ErbB-2; Trastuzumab; Immunoconjugates; Camptothecin; Humans; Female; Trastuzumab/therapeutic use; Camptothecin/therapeutic use; Breast Neoplasms/pathology; Immunoconjugates/therapeutic use; Brain Neoplasms/drug therapy; Brain Neoplasms/secondary; Brain Neoplasms; Breast Neoplasms; Oncology
Abstract :
[en] [en] UNLABELLED: DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%-77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7-18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation. SIGNIFICANCE: Advances in treating HER2-positive metastatic breast cancer have greatly improved patient outcomes, but intracranial progression remains an important risk for which few therapeutic options are currently available. T-DXd demonstrated durable efficacy in patients with stable, treated BMs. This article is highlighted in the In This Issue feature, p. 2711.
Disciplines :
Oncology
Author, co-author :
Jerusalem, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Park, Yeon Hee ;  Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea
Yamashita, Toshinari ;  Kanagawa Cancer Center, Yokohama, Japan
Hurvitz, Sara A ;  University of California, Los Angeles, Division of Hematology-Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
Modi, Shanu ;  Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Andre, Fabrice ;  Gustave Roussy, Department of Immunology, Université Paris-Sud, Villejuif, France
Krop, Ian E ;  Department of Medical Oncology, Yale Cancer Center, New Haven, Connecticut
Gonzàlez Farré, Xavier ;  Instituto Oncológico Dr Rosell, Hospital General De Catalunya, SOLTI, Institut Oncològic, Barcelona, Spain
You, Benoit ;  Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Department of Medical Oncology, Université Claude Bernard Lyon 1, Lyon, France
Saura, Cristina ;  Vall d'Hebron University Hospital, Breast Cancer Unit, Medical Oncology Service and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Kim, Sung-Bae ;  Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Osborne, Cynthia R ;  US Oncology Research, McKesson Specialty Health, The Woodlands, Texas ; Texas Oncology, Baylor-Sammons Cancer Center, Medical Services, Dallas, Texas
Murthy, Rashmi K ;  Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Gianni, Lorenzo ;  Department of Oncology, Infermi Hospital, AUSL della Romagna, Rimini, Italy
Takano, Toshimi ;  Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan
Liu, Yali ;  Daiichi Sankyo, Basking Ridge, New Jersey
Cathcart, Jillian ;  Daiichi Sankyo, Basking Ridge, New Jersey
Lee, Caleb ;  Daiichi Sankyo, Basking Ridge, New Jersey
Perrin, Christophe ;  Department of Oncology, Centre Eugène Marquis, Rennes, France
More authors (9 more) Less
Language :
English
Title :
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Publication date :
02 December 2022
Journal title :
Cancer Discovery
ISSN :
2159-8274
eISSN :
2159-8290
Publisher :
American Association for Cancer Research Inc., United States
Volume :
12
Issue :
12
Pages :
2754 - 2762
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
AstraZeneca [BE]
American Regent [US-NY] [US-NY]
Funding text :
Editorial assistance was provided by Jenna M. Gaska, PhD (Articu-lateScience, LLC), Jill Seabrook, PhD, and Laura Halvorson, PhD (ApotheCom), and financially supported by Daiichi Sankyo and AstraZeneca.
Available on ORBi :
since 16 February 2023

Statistics


Number of views
39 (1 by ULiège)
Number of downloads
50 (0 by ULiège)

Scopus citations®
 
19
Scopus citations®
without self-citations
19
OpenCitations
 
2

Bibliography


Similar publications



Contact ORBi